Green Leaf Pharmaceuticals anti-depressive drug LY03005 in the United States declared NDA.

The filing is based on consensus reached by Greenleaf Pharmaceuticals and the FDA at the End-Of-CMC Conference and the Pre-NDA Meeting.
LY03005 is an exclusive product of the central nervous system based on the company's new compound (NCE/NTE) platform.
it is a 5-serotonin-de-epinephrine-dopamine triple reuptake inhibitor (SNDRI), one of the active metabolites is a 5-serotonin-norepinephrine double reuptake inhibitor (SNRI).
depression is one of the most common diseases in the central nervous system, with more than 300 million patients worldwide.
the disease is the leading cause of disability around the world and a major contributor to the global burden of disease, with less than half of patients (less than 10 per cent in many countries) currently receiving effective treatment and the patient situation is critical.
generally speaking, traditional antidepressants, such as selective 5-serotonin reuptake inhibitors (SSRIs), 5-serotonin-norepinephrine reuptake inhibitors (SNRIs), have drug deficiencies such as lack of pleasure, sexual dysfunction, and failure to improve cognitive impairment, while serotonin-doophyrarepines-dopamine-dopamine reuptake inhibitors (SNDRIs) are expected to be more protective of function than traditional drugs.
Green Leaf Pharmaceuticals has patents covering LY03005 chemical compositions, crystal morphology and preparations. patents
chemical composition and crystal form have been obtained in China, the United States, Europe, Japan and Korea. "The global patient population in the field of central neurotherapy is large and growing, and this type of disease is a serious problem for both patients and their families," said the management of the
Green Leaf Pharmaceuticalgroup.
we want to provide more high-quality and innovative primary medicines to help more patients in need worldwide address their unmet clinical needs.
" At present, Green Leaf Pharmaceuticals is stepping up its investment efforts to promote the development of new drugs in the field of the disease.
several new drugs are in the NDA or clinical late stage, and are expected to be launched in 2020 in major pharmaceutical markets around the world.
in addition to LY03005, there are LY03004 (treatment of schizophrenia and bipolar disorder) that has been declared in the United States in March this year, and its production base has been approved by the U.S. FDA for pre-marketing tests;
these follow-up products will continue to enhance the core competitiveness of Green leaf pharmaceuticals globally in the field through market channels and a global supply chain system in more than 80 countries and regions currently covered by Green Leaf Pharmaceuticals, and a global supply chain system, with existing products in the field of disease, and further synergies.
.